Biotech Co.* (Country; Symbol) Pharma Co. (Country) Product Terms/Details (Date) Alpha Innotech Corp.* Panomics Inc. FluorChem fluorescence and chemiluminescence imaging system and the TranSignal chemiluminescense- based membrane array products Strategic alliance to jointly market their respective products (2/25) Atrix Laboratories Inc. (ATRX) Luxembourg Pharmaceuticals Ltd. (Israel) Eligard leuprolide acetate prostate cancer products Exclusive licensing agreement for the

Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date) 3M Drug Delivery Systems Division (NYSE:MMM) Novartis Pharma AG (Switzerland) inhalation products Agreement to explore future development and manufacturing opportunities for a range of new Novartis The deal is aimed at developing Novartis' pipeline of inhalation products that will be delivered via metered dose inhalers (4/9) Adolor Corp. (ADLR) GlaxoSmithKline plc (UK) Worldwide agreement

10 BIGGEST U.S. GAINERS FOR THE WEEK (By Percent) (By Dollars) Adolor 54.31 Trimeris 11.05 Avax Technol 45.00 Adolor 5.35 Cel-Sci 37.93 Vertex Pharma 3.46 British Biotech 35.40 Neurocrine Biosci 3.38 Onyx Pharma 34.06 Affymetrix 3.35 Trimeris 27.97 ICOS 3.06 Genz Mol Oncol 25.66 Progenics Pharma 2.64 Flamel Tech 24.42 IDEC Pharma 2.55 Oxis Int'l 23.81 Enzon 2.36 Orchid 21.96 Protein Design 2.35 10 BIGGEST U.S. LOSERS FOR THE WEEK (By Percent) (By Dollars) MGI Pharma

Editor Multiple sclerosis - as many of those afflicted know all too well - is characterized in extreme forms by tissue-hardening paralysis, during its often-painful march through the brains and spinal cords of victims. But the competitive arena for MS treatments has been anything but frozen in place, especially lately. The war of words and data picked up particular fervor last month. That's when Serono SA won U.S. approval of Rebif (interferon beta 1-a), thus dodging the orphan drug status

Company* (Symbol) Product Description Indication Status (Date) CANCER Celgene Corp. (CELG) Thalomid Thalidomide; modulates levels of tumor necrosis factor-alpha Multiple myeloma FDA said the company has to conduct a new trial in a different indication; the company will now pursue seeking approval of Thalomid in early stage multiple myeloma, instead of refractory/relapsed multiple myeloma (3/7) Corixa Corp. (CRXA) Bexxar Tositumomab, iodine-131; radioimmuno- therapy Non

Company* (Symbol) Product Description Indication Status (Date) CANCER Ark Therapeutics Ltd. (UK)* EG009 Gene therapy product consisting of the gene HSV-tk, and the inactive prodrug ganciclovir Glioma Product was granted orphan drug designation in the European Union (3/27**) Cell Therapeutics Ltd. (subsidiary of Cell Therapeutics Inc.; CTIC) Trisenox (FDA- approved) Arsenic trioxide injection Relapsed/refractory acute promyelocytic leukemia The European Commission granted

Figures from a financing of a non-biotech company were mistakenly included in the April 8, 2002, BioWorld Financial Watch issue. On page 4, the correct figure for the total of March follow-on offerings is $156.9 million. The number of follow-on offerings that occurred in March is four, and the average value of the March follow-ons is $39.225 million. The number of follow-ons in 2002 is 10, and the total raised in follow-ons in 2002 is $449.03 million. The average follow-on offering in 2002

Senior Staff Writer Cancer. Few words strike fear into the heart more than cancer. The disease kills with such proficiency that it is not particularly shocking when someone develops cancer, instead being more significant when cancer is actually defeated. Which, unfortunately, does not happen as often as patients, doctors and biotechnology companies would like. In the United States, HIV and AIDS in the late 1980s and early 1990s equaled cancer's level of fear inducement, perhaps achieving

Money Raised Year To Date

Company* (Symbol) Product Description Indication Status (Date) CANCER AltaRex Corp. (Canada; TSE:AXO) OvaRex Oregovomab; a fully foreign monoclonal antibody that targets CA 125 Advanced ovarian cancer Clinical data demonstrated a 41% reduced risk of relapse for OvaRex-treated patients compared to placebo, a result that is statistically significant; all studies to date demonstrate a benign safety profile (3/15); company saw positive primary results of its 20-patient chemo

I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $247.25M Company Location Date Amt. (M) Details Aegera Therapeutics Inc. Montreal 3/4 C$17 (US$10.7) Aegera raised US$10.7M in a private round co-led by Genechem Therapeutics Venture Fund LP and the Solidarity Fund; other investors were the Business Development Bank of Canada, Investissement Desjardins, Capital regional et cooperatif Desjardins, T2C2/Bio 2000 LP, CDP Sofinov, Innovatech Grand Montreal, Canadian Medical Discovery Fund

Total: $172.15M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@ Altachem Pharma Ltd. (Canada;CDNX:AAF) Private placement of units 8.5U C$10.2 (US$6.4) Altachem raised US$6.4M in a private placement of 8.5M units (3/1) Amrad Corporation Ltd. (Australia; ASX:AMC) Private placement of common stock N/A A$15.5 (US$7.9) Amrad raised US$7.9M from institutional investors (3/6**) AVI

I. COMMENCED TRADING IN MARCH Company (Symbol) Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M) Lead, Other Underwriters Gross (M) Post-Offering Market Cap (M) INITIAL OFFERINGS There were no initial public offerings conducted in March. Total: $0M Number of IPOs in March: 0 Average value of March IPOs: $0M Number of IPOs in 2002: 1 Total raised in IPOs in 2002: $128.8M* Average value of IPOs in 2002: $128.8M* *Figures include

Editor You don't hear the term "overnight sensation" much in biotechnology (in fact, you don't hear it much at all, now that variety show host Ed Sullivan is gone), but the tag seems just right for Alkermes Inc. even if those who know him might have difficulty imagining CEO Richard Pops onstage with a microphone, belting out tunes. The drug delivery company began singing a new and more expansive song, disclosing its $934 million agreement to buy the 81 percent of Reliant Pharmaceuticals LLC

Money Raised Year To Date

Money Raised Year To Date

I. MODIFIED AGREEMENTS Biotech Co.* (Country/Symbol) Biotech Co.* (Country/Symbol) Change from original agreement Disclosed Funding (M) Terms/Details (Date) Alliance Pharmaceutical Corp. (ALLP) Inhale Thera- peutics Systems Inc. (INHL) Expanded agreement regarding the Pulmo-Sphere particle and particle-processing technology ND As a result of the supplemental agreement, Inhale paid Alliance $5.25M in exchange for rights beyond inhaleable applications and other considerations (3/20

Biotech Co.* (Country/Symbol) Biotech Co.* (Country/Symbol) Product Disclosed Funding (M) Terms/Details (Date) Avid Bio- services Inc. (unit of Peregrine Pharmaceuticals Inc.; PPHM) Inhibitex Inc.* Therapeutic monoclonal antibodies ND Manufacturing and supply agreement for antibodies that will be used in future clinical studies (3/19) Eos Biotech- nology Inc.* ICOS Corp. (ICOS) CHEF1 enhanced mammalian protein expression technology ND A manufacturing and licensing

Company* (Country, Symbol) Company* (Country, Symbol) Type/Product Area Terms/Details (Date) 4SC AG (Germany)* Wilex AG (Germany)* Research collaboration to optimize and synthesize second-generation inhibitors of urokinase, a protein known to play a role in tumor metastasis 4SC will build and screen virtual combinatorial libraries for candidate compounds based on WX-293; in return, 4SC will receive research funding and milestone payments (1/14) Acadia Pharm- aceuticals Inc